234 related articles for article (PubMed ID: 28472073)
1. Aggressive rat prostate tumors reprogram the benign parts of the prostate and regional lymph nodes prior to metastasis.
Strömvall K; Thysell E; Halin Bergström S; Bergh A
PLoS One; 2017; 12(5):e0176679. PubMed ID: 28472073
[TBL] [Abstract][Full Text] [Related]
2. Highly aggressive rat prostate tumors rapidly precondition regional lymph nodes for subsequent metastatic growth.
Strömvall K; Lundholm M; Thysell E; Bergh A; Halin Bergström S
PLoS One; 2017; 12(10):e0187086. PubMed ID: 29073272
[TBL] [Abstract][Full Text] [Related]
3. Reduced number of CD169
Strömvall K; Sundkvist K; Ljungberg B; Halin Bergström S; Bergh A
Prostate; 2017 Nov; 77(15):1468-1477. PubMed ID: 28880401
[TBL] [Abstract][Full Text] [Related]
4. Adaptive (TINT) Changes in the Tumor Bearing Organ Are Related to Prostate Tumor Size and Aggressiveness.
Adamo HH; Strömvall K; Nilsson M; Halin Bergström S; Bergh A
PLoS One; 2015; 10(11):e0141601. PubMed ID: 26536349
[TBL] [Abstract][Full Text] [Related]
5. Prostate tumors downregulate microseminoprotein-beta (MSMB) in the surrounding benign prostate epithelium and this response is associated with tumor aggressiveness.
Bergström SH; Järemo H; Nilsson M; Adamo HH; Bergh A
Prostate; 2018 Mar; 78(4):257-265. PubMed ID: 29250809
[TBL] [Abstract][Full Text] [Related]
6. Prostate cancer induces C/EBPβ expression in surrounding epithelial cells which relates to tumor aggressiveness and patient outcome.
Adamo H; Hammarsten P; Hägglöf C; Dahl Scherdin T; Egevad L; Stattin P; Halin Bergström S; Bergh A
Prostate; 2019 Apr; 79(5):435-445. PubMed ID: 30536410
[TBL] [Abstract][Full Text] [Related]
7. Extratumoral Heme Oxygenase-1 (HO-1) Expressing Macrophages Likely Promote Primary and Metastatic Prostate Tumor Growth.
Halin Bergström S; Nilsson M; Adamo H; Thysell E; Jernberg E; Stattin P; Widmark A; Wikström P; Bergh A
PLoS One; 2016; 11(6):e0157280. PubMed ID: 27280718
[TBL] [Abstract][Full Text] [Related]
8. Extracellular Vesicles from Metastatic Rat Prostate Tumors Prime the Normal Prostate Tissue to Facilitate Tumor Growth.
Halin Bergström S; Hägglöf C; Thysell E; Bergh A; Wikström P; Lundholm M
Sci Rep; 2016 Aug; 6():31805. PubMed ID: 27550147
[TBL] [Abstract][Full Text] [Related]
9. Characterization of a Gene Expression Signature in Normal Rat Prostate Tissue Induced by the Presence of a Tumor Elsewhere in the Organ.
Adamo HH; Halin Bergström S; Bergh A
PLoS One; 2015; 10(6):e0130076. PubMed ID: 26076453
[TBL] [Abstract][Full Text] [Related]
10. Transforming growth factor-beta 1: comparative immunohistochemical localization in human primary and metastatic prostate cancer.
Eastham JA; Truong LD; Rogers E; Kattan M; Flanders KC; Scardino PT; Thompson TC
Lab Invest; 1995 Nov; 73(5):628-35. PubMed ID: 7474936
[TBL] [Abstract][Full Text] [Related]
11. The role of P501S and PSA in the diagnosis of metastatic adenocarcinoma of the prostate.
Sheridan T; Herawi M; Epstein JI; Illei PB
Am J Surg Pathol; 2007 Sep; 31(9):1351-5. PubMed ID: 17721190
[TBL] [Abstract][Full Text] [Related]
12. Rat prostate tumors induce DNA synthesis in remote organs.
Halin Bergström S; Lundholm M; Nordstrand A; Bergh A
Sci Rep; 2022 May; 12(1):7908. PubMed ID: 35551231
[TBL] [Abstract][Full Text] [Related]
13. Prediction of pelvic lymph node metastasis by the ratio of cathepsin B to stefin A in patients with prostate carcinoma.
Sinha AA; Quast BJ; Wilson MJ; Fernandes ET; Reddy PK; Ewing SL; Gleason DF
Cancer; 2002 Jun; 94(12):3141-9. PubMed ID: 12115346
[TBL] [Abstract][Full Text] [Related]
14. Prediction of immune surveillance responsive metastatic prostate cancer in pelvic lymph node and emergence of surveillance unresponsive/resistant metastatic cells.
Sinha AA; Fernandes ET; Ewing SL; Wilson MJ
Anticancer Res; 2013 Sep; 33(9):3635-43. PubMed ID: 24023290
[TBL] [Abstract][Full Text] [Related]
15. Tumor-secreted vascular endothelial growth factor-C is necessary for prostate cancer lymphangiogenesis, but lymphangiogenesis is unnecessary for lymph node metastasis.
Wong SY; Haack H; Crowley D; Barry M; Bronson RT; Hynes RO
Cancer Res; 2005 Nov; 65(21):9789-98. PubMed ID: 16267000
[TBL] [Abstract][Full Text] [Related]
16. Proteomic analysis of dunning prostate cancer cell lines with variable metastatic potential using SELDI-TOF.
Gretzer MB; Chan DW; van Rootselaar CL; Rosenzweig JM; Dalrymple S; Mangold LA; Partin AW; Veltri RW
Prostate; 2004 Sep; 60(4):325-31. PubMed ID: 15264244
[TBL] [Abstract][Full Text] [Related]
17. The lymph node as a bridgehead in the metastatic dissemination of tumors.
Sleeman JP
Recent Results Cancer Res; 2000; 157():55-81. PubMed ID: 10857162
[TBL] [Abstract][Full Text] [Related]
18. Orthotopic treatment model of prostate cancer and metastasis in the immunocompetent mouse: efficacy of flt3 ligand immunotherapy.
Somers KD; Brown RR; Holterman DA; Yousefieh N; Glass WF; Wright GL; Schellhammer PF; Qian J; Ciavarra RP
Int J Cancer; 2003 Dec; 107(5):773-80. PubMed ID: 14566827
[TBL] [Abstract][Full Text] [Related]
19. Systemic interleukin 2 therapy for human prostate tumors in a nude mouse model.
Triest JA; Grignon DJ; Cher ML; Kocheril SV; Montecillo EJ; Talati B; Tekyi-Mensah S; Pontes JE; Hillman GG
Clin Cancer Res; 1998 Aug; 4(8):2009-14. PubMed ID: 9717832
[TBL] [Abstract][Full Text] [Related]
20. Traffic to lymph nodes of PC-3 prostate tumor cells in nude mice visualized using the luciferase gene as a tumor cell marker.
Rubio N; Villacampa MM; Blanco J
Lab Invest; 1998 Oct; 78(10):1315-25. PubMed ID: 9800957
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
